- Home
- CHRS vs LGI Comparison
CHRS vs LGI Comparison
Compare CHRS & LGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- LGI
- Stock Information
- Founded
- CHRS 2010
- LGI 2004
- Country
- CHRS United States
- LGI United States
- Employees
- CHRS N/A
- LGI N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- LGI
- Sector
- CHRS Health Care
- LGI
- Exchange
- CHRS Nasdaq
- LGI Nasdaq
- Market Cap
- CHRS 194.1M
- LGI 224.1M
- IPO Year
- CHRS 2014
- LGI N/A
- Fundamental
- Price
- CHRS $1.69
- LGI $16.89
- Analyst Decision
- CHRS Strong Buy
- LGI
- Analyst Count
- CHRS 4
- LGI 0
- Target Price
- CHRS $4.51
- LGI N/A
- AVG Volume (30 Days)
- CHRS 1.4M
- LGI 41.1K
- Earning Date
- CHRS 11-05-2025
- LGI 01-01-0001
- Dividend Yield
- CHRS N/A
- LGI 7.10%
- EPS Growth
- CHRS N/A
- LGI N/A
- EPS
- CHRS 1.55
- LGI N/A
- Revenue
- CHRS $272,209,000.00
- LGI N/A
- Revenue This Year
- CHRS N/A
- LGI N/A
- Revenue Next Year
- CHRS $109.48
- LGI N/A
- P/E Ratio
- CHRS $3.27
- LGI N/A
- Revenue Growth
- CHRS 52.33
- LGI N/A
- 52 Week Low
- CHRS $0.66
- LGI $12.66
- 52 Week High
- CHRS $2.43
- LGI $16.68
- Technical
- Relative Strength Index (RSI)
- CHRS 62.59
- LGI 32.29
- Support Level
- CHRS $1.63
- LGI $17.54
- Resistance Level
- CHRS $1.89
- LGI $17.74
- Average True Range (ATR)
- CHRS 0.12
- LGI 0.24
- MACD
- CHRS 0.00
- LGI -0.05
- Stochastic Oscillator
- CHRS 64.42
- LGI 0.00
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About LGI Lazard Global Total Return and Income Fund
Lazard Global Total Return & Inc Fd Inc is a United States-based diversified, closed-end management investment company. Its investment objective is total return consisting of capital appreciation and income. The fund's portfolio of investments consists of different sector investments such as consumer staples, financials, consumer discretionary, healthcare, materials, sovereign debt and others.